+1,470.1%
QBTS vs MRNA
+34.8%
+1,435.3%
-71.0%
Performance
Returns, benchmark comparison, and relative performance.
Performance by timeframe
Returns for 3y.
| Period | Portfolio | MRNA | Excess | Alpha |
|---|---|---|---|---|
| 1D | +0.8% | +5.4% | -4.5% | +0.2% |
| 7D | +1.3% | -1.1% | +2.4% | +1.4% |
| 30D | -19.0% | +126.1% | -145.1% | -33.9% |
| 3M | -29.5% | +190.0% | -219.5% | -48.8% |
| 6M | -11.2% | +157.2% | -168.4% | -32.1% |
| YTD | -35.8% | +388.2% | -424.0% | -63.3% |
| 1Y | +1.7% | +467.0% | -465.3% | -45.8% |
| 3Y | +1,470.1% | +36.1% | +1,434.0% | +1,014.6% |
| All | +1,470.1% | +34.8% | +1,435.3% | +1,014.6% |
Cumulative growth
Daily Returns
Daily percentage return beside MRNA.
Daily Out/Under-Performance
Portfolio return minus MRNA return. Positive bars indicate outperformance.
Daily Alpha
Portfolio daily return minus β × MRNA return. Early observations use the first valid beta; later observations use the trailing beta estimated for each date.
Cumulative Out/Under-Performance
Relative wealth over 3y: compounded portfolio wealth divided by compounded MRNA wealth, less one. Both series rebase at the selected span's start.
Cumulative Alpha
Compounded beta-adjusted residual returns apply the first valid beta to early observations, then the trailing beta ending on each date.
Updating return analytics…
3y analysis · Full analysis span regression · 6 months rolling